After 72 h and 96 h of treatment, the sensitivity of all MM cell lines to Erk1/2i increased, with IC50 of 0.1–0.5 μM in RAS-MT cells and IC50 of 1–3 μM in WT cells (Fig. 1B2–3C, Fig. S1D). The gene discussed is MAPK3; the disease is Miyoshi myopathy.